Author
Listed:
- Kevin Elias
(Brigham and Women’s Hospital)
- Urszula Smyczynska
(Medical University of Lodz)
- Konrad Stawiski
(Medical University of Lodz)
- Zuzanna Nowicka
(Medical University of Lodz)
- James Webber
(Brigham and Women’s Hospital)
- Jakub Kaplan
(Dana-Farber Cancer Institute)
- Charles Landen
(University of Virginia)
- Jan Lubinski
(International Hereditary Cancer Center of the Pomeranian Medical University)
- Asima Mukhopadhyay
(Kolkata Gynecology Oncology Trials and Translational Research Group)
- Dona Chakraborty
(Kolkata Gynecology Oncology Trials and Translational Research Group)
- Denise C. Connolly
(Fox Chase Cancer Center)
- Heather Symecko
(University of Pennsylvania)
- Susan M. Domchek
(University of Pennsylvania)
- Judy E. Garber
(Dana-Farber Cancer Institute
Harvard Medical School)
- Panagiotis Konstantinopoulos
(Dana-Farber Cancer Institute
Harvard Medical School)
- Wojciech Fendler
(Medical University of Lodz
Dana-Farber Cancer Institute)
- Dipanjan Chowdhury
(Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Harvard Medical School)
Abstract
Identifying germline BRCA1/2 mutation carriers is vital for reducing their risk of breast and ovarian cancer. To derive a serum miRNA-based diagnostic test we used samples from 653 healthy women from six international cohorts, including 350 (53.6%) with BRCA1/2 mutations and 303 (46.4%) BRCA1/2 wild-type. All individuals were cancer-free before and at least 12 months after sampling. RNA-sequencing followed by differential expression analysis identified 19 miRNAs significantly associated with BRCA mutations, 10 of which were ultimately used for classification: hsa-miR-20b-5p, hsa-miR-19b-3p, hsa-let-7b-5p, hsa-miR-320b, hsa-miR-139-3p, hsa-miR-30d-5p, hsa-miR-17-5p, hsa-miR-182-5p, hsa-miR-421, hsa-miR-375-3p. The final logistic regression model achieved area under the receiver operating characteristic curve 0.89 (95% CI: 0.87–0.93), 93.88% sensitivity and 80.72% specificity in an independent validation cohort. Mutated gene, menopausal status or having preemptive oophorectomy did not affect classification performance. Circulating microRNAs may be used to identify BRCA1/2 mutations in patients of high risk of cancer, offering an opportunity to reduce screening costs.
Suggested Citation
Kevin Elias & Urszula Smyczynska & Konrad Stawiski & Zuzanna Nowicka & James Webber & Jakub Kaplan & Charles Landen & Jan Lubinski & Asima Mukhopadhyay & Dona Chakraborty & Denise C. Connolly & Heathe, 2023.
"Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles,"
Nature Communications, Nature, vol. 14(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38925-4
DOI: 10.1038/s41467-023-38925-4
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-38925-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.